Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Multicenter, Placebo-controlled, Double-blind Clinical Study of the Safety and Efficacy of Carrimycin for Treatment of Severe COVID-19 in Hospitalized Patients

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized, Multicenter, Placebo-controlled, Double-blind Clinical Study of the Safety and Efficacy of Carrimycin for Treatment of Severe COVID-19 in Hospitalized Patients

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carrimycin (Primary)
  • Indications COVID 2019 infections; COVID-19 respiratory infection
  • Focus Registrational; Therapeutic Use
  • Sponsors Shenyang Tonglian Group

    • Most Recent Events

    • 22 Feb 2023 Status changed from suspended to discontinued.
    • 05 Aug 2022 Status changed from recruiting to suspended because of change in sponsor strategy.
    • 13 Jul 2022 Planned End Date changed from 28 Jul 2022 to 25 Nov 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top